US · Healthcare · Biotechnology
EPS came in at -0.26 against a street estimate of -0.32 — a beat of 18.8%.
Analysts rate Silence Therapeutics PLC a buy (6 buy, 0 hold, 1 sell out of 7) with an average price target of $33.00.
| Fund | Stake |
|---|---|
| Siren, L.L.C. | 5.33% |
| TCG Crossover Management, LLC | 4.88% |
| Nantahala Capital Management, LLC | 4.33% |
| Redmile Group, LLC | 3.48% |
| Citadel Advisors Llc | 2.14% |
| Nextech Invest, Ltd. | 1.53% |
| Millennium Management LLC | 1.46% |
| Ikarian Capital, LLC | 1.34% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 SILENCE THERAPEUTICS PLC - 8-K SUMMARY HEADLINE NUMBERS • Public offering size: 12,962,963 American Depositary Shares (ADSs) at $13.50 per ADS • Und | 2026-08-12 |
| Quarterly report · Q2 2026 SILENCE THERAPEUTICS PLC – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $72.1 million in cash and cash equivalents as of June 30, 2026, | 2026-08-10 |
| Reg FD disclosure · Q3 2026 SILENCE THERAPEUTICS PLC – 8-K SUMMARY HEADLINE NUMBERS • Primary endpoint met: 88% of divesiran-treated patients achieved clinical response versus | 2026-08-10 |
| Results announced · Q3 2026 SILENCE THERAPEUTICS Q2 2026 FINANCIAL & BUSINESS RESULTS HEADLINE NUMBERS • Cash position: $72.1 million as of June 30, 2026 (up from $11.3 million | 2026-08-10 |
| Reg FD disclosure · Q2 2026 SILENCE THERAPEUTICS PLC – 8-K SUMMARY HEADLINE NUMBERS • Filing Date: June 23, 2026 • Company: Silence Therapeutics plc, England and Wales incorpora | 2026-06-23 |
| Quarterly report · Q1 2026 SILENCE THERAPEUTICS PLC – 10-Q SUMMARY For the Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash and short-term investments: $70.1 million | 2026-05-07 |
| Proxy statement · Q2 2026 SILENCE THERAPEUTICS PLC – PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Resolution 1: Re-appoint Rhonda Hellums as director • Resolutio | 2026-04-29 |
| Annual report FY2025 SILENCE THERAPEUTICS PLC - 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Silence Therapeutics plc, England-based biotechnology firm | 2026-03-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Silence Therapeutics PLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.